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Background/Aims
Environmental factors such as food, lifestyle and prevalence of Helicobacter pylori infection are widely different in Asian coun-
tries compared to the West, and physiological functions and genetic factors of Asians may also be different from those of 
Westerners. Establishing an Asian consensus for functional dyspepsia is crucial in order to attract attention to such data from 
Asian countries, to articulate the experience and views of Asian experts, and to provide a relevant guide on management of 
functional dyspepsia for primary care physicians working in Asia.
Methods
Consensus team members were selected from Asian experts and consensus development was carried out using a modified 
Delphi method. Consensus teams collected published papers on functional dyspepsia especially from Asia and developed candi-
date consensus statements based on the generated clinical questions. At the first face-to-face meeting, each statement was 
reviewed and e-mail voting was done twice. At the second face-to-face meeting, final voting on each statement was done us-
ing keypad voting system. A grade of evidence and a strength of recommendation were applied to each statement according 
to the method of the GRADE Working Group.
Results
Twenty-nine consensus statements were finalized, including 7 for definition and diagnosis, 5 for epidemiology, 9 for patho-
physiology and 8 for management. Algorithms for diagnosis and management of functional dyspepsia were added.
Conclusions
This consensus developed by Asian experts shows distinctive features of functional dyspepsia in Asia and will provide a guide 
to the diagnosis and management of functional dyspepsia for Asian primary care physicians.
(J Neurogastroenterol Motil 2012;18:150-168)
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Introduction
Dyspepsia is one of the most common disorders in medicine, 
with dyspeptic patients seen on a daily basis not only by gastro-
enterologists but also by physicians in a variety of other fields. 
However, organic causes are found in only a minority of such 
patients. Functional dyspepsia (FD) is defined as a condition in 
which upper abdominal symptoms occur in the absence of organ-
ic disease that explains them. There are many FD patients in 
Asian as well as Western countries. The scientific investigation of 
the pathophysiology of FD began only recently and its first defi-
nition was developed in 1988.
1 Since then, many of the ideas on 
this condition have been derived from studies conducted in 
Western societies, despite the large number of FD patients in 
Asian populations and much important research from Asian 
countries. 
Accordingly, the establishment of an Asian consensus for FD 
is crucial in order to attract attention to such data from Asian 
countries, to articulate the experience and views of Asian experts, 
and to provide a relevant guide to the management of this disease 
for primary care physicians working in Asia. In particular, envi-
ronmental factors such as food, lifestyle and prevalence of 
Helicobacter pylori infection are widely different in Asian countries 
compared to the West, and physiological functions and genetic 
factors of Asians may also be different from those of Westerners. 
Therefore, the Asian perspective should be useful for further un-
derstanding the pathogenesis of FD.
The understanding of FD is progressing and will evolve over 
time. We have summarized the current Asian perspective on FD 
in this consensus report, which will be revised as our under-
standing of FD grows. 
Methods
The Asian Neurogastroenterology and Motility Association 
(ANMA) and the Asian Pacific Association of Gastroenterology 
(APAGE) agreed to jointly generate an Asian consensus report 
on FD and organized 4 teams for that purpose: Team 1, defi-
nition and diagnosis; Team 2, epidemiology; Team 3, patho-
physiology; and Team 4, management. Twenty-two consensus 
team members were recruited from Asian countries on the basis 
of each member’s scientific activities and published papers on 
FD.
The consensus development process was carried out by using 
a modified Delphi method.
2 Consensus team members started 
their job in late June 2009 by collecting original papers on FD 
from Asian countries until the end of August 2009 through avail-
able global and domestic online literature searching systems. 
Papers in English and other languages that were not available on-
line were searched manually. Thereafter the remaining important 
original and review papers not only from Asia but also from rest 
of the world were also collected and added. When a new paper 
was published during the consensus process, it was also included. 
After thorough reviewing of the literature, each team generated 
approximately 10 consensus statements through intra- and in-
ter-team e-mail discussions, resulting in a total of 37 candidate 
consensus statements.
On September 19, 2010, the first Asian FD consensus meet-
ing was held in Kuala Lumpur, Malaysia. At the meeting, each 
candidate statement was discussed in depth, and afterward, the 
statements were reviewed again and amended by the 4 teams, tak-
ing the discussions held at the first consensus meeting into 
consideration. At this point, 34 consensus statements had been 
developed.
The first e-mail voting on the consensus statements was done 
by all of the consensus members on October 26, 2010. Each 
member was asked to choose one of the following 6 levels of 
agreement on each statement (Table): (a) accept completely, (b) 
accept with minor reservation, (c) accept with major reservation, 
(d) reject with major reservation, (e) reject with minor reser-
vation, and (f) reject completely. Consensus members were also 
asked to add comments on each statement, if any. When the pro-
portion of members who voted (a) or (b) was 80% or higher, the 
statement was regarded as acceptable and a consensus was con-
sidered to have been reached. In the first e-mail vote, 25 of the 34 
statements (73.5%) were acceptable and the remaining 9 state-
ments (26.5%) failed to reach the consensus level. 
After extensive discussions and subsequent revision of the 
consensus statements, the second e-mail voting was done on 35 
statements on January 11, 2011. From this voting, 30 statements 
(85.7%) were acceptable while 5 statements (14.3%) were un-
acceptable. Each statement was reviewed and amended again by 
each team, and a total of 32 consensus statements were developed 
for final voting.
On March 3, 2011, the second Asian FD consensus meeting 
was held in Beijing, China. At the plenary meeting, voting on 
each statement was done using a keypad voting system. After 
each vote, a discussion was held, and if necessary, the statement 
was revised and voted on again until a consensus was reached. At Hiroto Miwa, et al
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Category Description
Grade of evidence
High Further research is unlikely to change our confidence in the estimate of effect
Moderate
Further research is likely to have an important impact on our confidence in the estimate of effect and might change 
the estimate
Low
Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely 
to change the estimate
Very low Any estimate of effect is very uncertain
Level of agreement
a
a Accept completely
b Accept with minor reservation
c Accept with major reservation
d Reject with major reservation
e Reject with minor reservation
f Reject completely
Strength of recommendation
Do it A judgment that most well-informed people would make
Probably do it A judgment that a majority of well-informed people would make but a substantial minority would not
Probably not do it A judgment that a majority of well-informed people would make but a substantial minority would not
Not do it A judgment that most well-informed people would make
aEach statement was accepted when 80% or more of participants voted a or b.
Table. Grade of Evidence, Level of Agreement and Strength of Recommendation
the conclusion of this process, 29 consensus statements (7 on def-
inition and diagnosis, 5 on epidemiology, 9 on pathophysiology 
and 8 on management) had been finalized. A grade of evidence 
and a strength of recommendation were applied to each statement 
according to the GRADE Working Group (Table).
3 Algo-
rithms for diagnosis (Fig. 1) and management (Fig. 2) of FD 
were made after the statements had been finalized.
Consensus Statements
Definition and Diagnosis
Statement 1. Dyspepsia refers to a symptom or set of 
symptoms that is (are) considered to originate from the 
gastroduodenal region. The dyspeptic symptoms are 
epigastric pain, epigastric burning, postprandial fullness, 
early satiation and others, including bloating in the upper 
abdomen, nausea, vomiting and belching.
Grade of evidence: not applicable.
Level of agreement: a: 89.5%; b: 5.3%; c: 5.3%; d: 0%; e: 
0%; f: 0%.
For this statement, the consensus members decided to follow 
the concept of the Rome III Committee that dyspepsia is a symp-
tom or a group of symptoms that is (are) considered to originate 
from the gastroduodenal region.
4
However, the consensus members agreed to include upper 
abdominal bloating which is a common FD symptom. Although 
there are limited data on the prevalence of upper abdominal 
bloating in FD in Asia, most of the consensus members felt that 
this symptom is very common in Asian dyspeptic patients. It was 
reported that bloating was present in about half of the dyspeptic 
patients in the United States
5,6 and was most common in patients 
with dysmotility-like dyspepsia.
5 Studies in Korea and Japan 
demonstrated that postprandial distress syndrome (dysmotility- 
like dyspepsia) was present in 69.9% and 81.3% of patients with 
dyspepsia,
7 respectively. The overlapping of FD with other gas-
trointestinal (GI) motility disorders is common in Asia. It was re-
ported that about one fourth of FD patients in China had over-
lapping irritable bowel syndrome (IBS).
8
Statement 2. Functional dyspepsia is a condition charac-
terized by chronic dyspeptic symptoms in the absence of 
organic, systemic or metabolic condition(s) that is (are) 
likely to explain the symptoms (see Fig. 1).
Grade of evidence: not applicable.
Level of agreement: a: 89.5%; b: 10.5%; c: 0%; d: 0%; e: 
0%; f: 0%.
The consensus members agreed that chronic dyspeptic symp-
toms could be continuous, intermittent or recurrent. However, Asian Consensus Report on Functional Dyspepsia
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Figure 1. Diagnostic algorithm for functional dyspepsia in Asian primary care settings. 
aDyspepsia refers to a symptom or set of symptoms that are 
considered to originate from the gastroduodenal region. The dyspeptic symptoms are epigastric pain, epigastric burning, postprandial 
fullness, early satiation and other symptoms including bloating in the upper abdomen, nausea, vomiting and belching. Chronic dyspeptic
symptoms can be continuous, intermittent or recurrent. More than two thirds of the consensus members agreed that symptom duration of
3 months or longer might be enough. 
bThe alarm features are unintended weight loss, progressive dysphagia, recurrent or persistent 
vomiting, evidence of gastrointestinal bleeding, anemia, fever, family history of gastric cancer, new onset dyspepsia in the subjects over 40
years of age in population with high prevalence of upper gastrointestinal malignancy and over 45 and 50 years in populations with 
intermediate and low prevalence, respectively. 
cThe appropriate choice from the three options depends on patient’s symptom profiles, 
patient’s wish, local risk of Helicobacter pylori infection and gastric cancer as well as local health care or re-imbursement system. H. pylori, 
Helicobacter pylori.
symptom duration of 6 months or longer was considered too long 
to make a diagnosis of FD in Asia. A study in Japan suggested 
that most patients with dyspeptic symptoms present to their doc-
tors within 6 months after the first appearance of their symp-
toms.
7 Twenty-six percent of the consensus members felt that in 
clinical practice a symptom duration of one month is enough to 
consider dyspeptic symptoms as being chronic, whereas 68% 
agreed with a duration of 3 months and only 5% agreed with the 
6-month period as in the Rome III criteria (Fig. 1). However, 
most of the consensus members agreed that for research pur-
poses, diagnosis of FD in Asia could follow the Rome III diag-
nostic criteria for FD.
Many organic, systemic or metabolic conditions such as pep-
tic ulcer diseases, cancers of the GI and hepatobiliary tract,
9,10 
parasitic infestations,
11-14 chronic pancreatic diseases,
15 hyper- 
and hypothyroidisms,
16 chronic renal failures,
17 and electrolyte 
imbalances, as well as medications, can produce symptoms similar 
to FD and should be considered before making a diagnosis of FD.
Statement 3. Diagnosis of functional dyspepsia and 
functional dyspepsia subgroups based on the Rome III 
criteria needs validation in Asia.
Grade of evidence: low.
Level of agreement: a: 100%; b: 0%; c: 0%; d: 0%; e: 0%; f: 
0%.
All consensus members agreed with this statement. Since 
Asian countries have large differences in culture and language, 
the interpretation of GI symptoms is likely to be different from 
country to country. Unfortunately, there are no cross-ethnic or Hiroto Miwa, et al
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Figure 2. Management algorithm for functional dyspepsia in Asian primary care settings.
 aWhere socio-economic conditions allow, Helicobacter pylori
test and eradication should be part of the management strategy for all patients presenting with dyspepsia in Asia.
 bSpecific food ingredients
may provoke dyspeptic symptoms. Dietary modification can be considered in functional dyspepsia but data are lacking. 
cWhere there is any
available herbal medication previously validated, it may be tried. H. pylori, Helicobacter pylori. 
cross-cultural studies to address this thesis currently.
Statement 4. A diagnosis of functional dyspepsia can be 
considered on the basis of clinical symptoms and upper 
gastrointestinal endoscopy results (see Fig. 1).
Grade of evidence: moderate.
Level of agreement: a: 78.9%; b: 15.8%; c: 5.3%; d: 0%; e: 
0%; f: 0%.
Most of the consensus members agreed that for most patients 
with dyspeptic symptoms in Asia the clinical symptoms and up-
per GI endoscopic results are sufficient to consider a diagnosis of 
FD. However, several studies in Asia also included upper ab-
dominal ultrasound as an important investigative tool for diag-
nosis of FD.
18,19 Some patients with clinical features that cannot 
be explained by endoscopic findings may need further diagnostic 
investigations such as stool examination for parasites and occult 
blood, if clinically indicated (Fig. 1). For a diagnosis of FD, the 
upper GI endoscopic results should include no evidence of any 
diseases and conditions that can explain the dyspeptic symptoms. 
The presence of H. pylori infection in the absence of positive en-
doscopic findings does not exclude a diagnosis of FD presently.
Statement 5. Dyspepsia patients with alarm features 
should be investigated before the diagnosis of functional 
dyspepsia is accepted (see Fig. 1).
Grade of evidence: high.
Level of agreement: a: 94.7%; b: 5.3%; c: 0%; d: 0%; e: 0%; 
f: 0%.
Although several studies suggested that alarm features have a 
low positive predictive value for the diagnosis of organic causes in 
patients with dyspepsia,
20 all of the consensus members agreed 
that if patients have any alarm features they should be inves-
tigated (Fig. 1). The alarm features are as follows: unintended 
weight loss; progressive dysphagia; recurrent or persistent vomit-
ing; evidence of GI bleeding; anemia; fever; family history of 
gastric cancer; and new onset dyspepsia in a patient over 40 years Asian Consensus Report on Functional Dyspepsia
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of age in a population with high prevalence of upper GI malig-
nancy, or over 45 or 50 years in a population with intermediate or 
low prevalence, respectively (see under Statement 8 for further 
discussion).
According to a recent review on the prevalence of gastric can-
cer in Asian countries,
21 China, Korea and Japan are high-risk 
countries; Hong Kong, Malaysia, Singapore, Taiwan and Viet-
nam are intermediate-risk countries; and Bangladesh, India and 
Thailand are low-risk countries. It has been reported in Japan 
that most patients with early gastric cancer are asymptomatic and 
lack alarm features.
10 Therefore, for early detection of gastric 
cancer in countries with high gastric cancer prevalence, doctors 
should follow their national gastric cancer screening guidelines 
instead of this dyspepsia consensus statement.
Statement 6. Other useful investigations for dyspepsia 
include complete blood cell count and blood bioche-
mistry tests. Patients with dyspepsia should be tested for 
Helicobacter pylori infection. Stool examination for 
parasites in areas with high prevalence of infestations and 
fecal blood testing are also useful. Upper abdominal 
u l t r a s o u n d  o r  C T  s c a n  m a y  b e  e m p l o y e d  i f  i n d i c a t e d  
clinically (see Fig. 1).
Grade of evidence: moderate.
Level of agreement: a: 52.6%; b: 36.8%; c: 10.5%; d: 0%; e: 
0%; f: 0%.
Most consensus members agreed that, if clinically indicated, 
complete blood count and blood biochemistry tests including 
tests for creatinine,
17 electrolytes, sugar, thyroid function
16and 
liver function are useful for identifying underlying causes that 
may produce dyspeptic symptoms (Fig. 1). Although H. pylori 
testing is not used for diagnosis of FD, it is useful for the man-
agement of FD patients. Role of H. pylori is discussed under 
Statement 18. In areas with high prevalence of parasitic in-
festations, a stool examination for parasites is useful for identi-
fication of parasitic infestations such as ascariasis,
14 fascioliasis,
11 
giardia lamblia
12 and opisthorchiasis
13 that can cause dyspeptic 
symptoms. Upper abdominal ultrasound or CT scan can be em-
ployed if clinically indicated, especially in areas with high preva-
lence of liver cancers that can present with dyspeptic symptoms.
10 
Statement 7. Gastric sensorimotor function tests 
including gastric emptying or accommodation studies 
may be useful in some subgroups of patients but are not 
recommended as routine clinical tests. 
Grade of evidence: high.
Level of agreement: a: 84.2%; b: 10.5%; c: 5.3%; d: 0%; e: 
0%; f: 0%.
Gastric function tests including gastric emptying test, elec-
trogastrography, water load test, gastric accommodation test and 
gastric sensation test play controversial roles in the diagnosis and 
management of FD.
22 These tests are poorly associated with dys-
peptic symptoms and cannot predict a response to medical ther-
apy in FD. Therefore, these tests should be reserved only for clin-
ical research studies and evaluation in some specific subgroups of 
dyspeptic patients, such as patients with diabetic gastroparesis or 
generalized GI motility disorders.
Epidemiology
Statement 8. In Asian populations, the majority of 
patients with uninvestigated dyspepsia without alarm 
features have functional dyspepsia.
Grade of evidence: moderate.
Level of agreement: a: 68.4%; b: 21.1%; c: 10.5%; d: 0%; e: 
0%; f: 0%.
In most studies from Asia, FD was diagnosed in most pa-
tients with uninvestigated dyspepsia (UD) after upper GI 
endoscopy.
23 In a Chinese study of 782 patients with UD, 69% 
turned out to have FD and the remaining 31% had organic 
causes.
24 In a multi-center Asian study of 1,115 patients with UD 
(Rome II criteria) from 9 countries (China, Hong Kong, 
Indonesia, Korea, Malaysia, Singapore, Taiwan, Thailand and 
Vietnam), 43% turned out to have FD after investigations.
25 In a 
Korean study of 476 patients with uninvestigated GI symptoms, 
70% had functional GI disorders according to the Rome II cri-
teria and 37% had FD.
26 In a Malaysian study of 210 young pa-
tients with UD, 62% were diagnosed with FD.
27 In a Singapor-
ean study, 988 of 5,066 patients with UD had organic causes and 
the remaining 79.5% had FD.
28 
The cut-off age for considering a feature to be an alarm fea-
ture may vary in different populations based on the local epi-
demiological pattern of gastric cancer. In a Japanese study that 
considered 50 years as the cut-off age, frequency of FD was 
found to be lower among persons older than 50 years.
29 In anoth-
er study from Japan, of 1,730 gastric cancer patients, 27 were less 
than 34 years old.
30 A study from India showed that patients with 
gastric cancer were older than patients with non-ulcer dyspepsia 
(53 ± 12 years vs 43 ± 13 years).
31 These data might suggest 
that the cut-off age for considering endoscopic examination may 
vary by geographical area, though most believe that it should be 
45 years of age.Hiroto Miwa, et al
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Statement 9. A portion of Asian patients with functional 
dyspepsia has overlapping irritable bowel syndrome.
Grade of evidence: moderate.
Level of agreement: a: 100.0%; b: 0%; c: 0%; d: 0%; e: 0%; 
f: 0%.
In Asian patients, there is a significant overlap between FD 
and IBS. In a Chinese study using the Rome III criteria, 24.8% 
of FD patients had overlapping IBS.
8 In a study from India, dys-
pepsia-IBS overlap (dyspepsia was defined as abdominal pain or 
discomfort centered in the upper abdomen and IBS by 
Manning’s criteria) was found in 14.2% of the FD subjects.
32 
Another Indian multi-center study demonstrated a high fre-
quency (90%) of upper abdominal pain or discomfort in IBS pa-
tients, although the diagnosis in that study was based on the clini-
cians’ assessment rather than on the Rome criteria.
33 In a 
Japanese study, the overlap of FD and IBS was found to be 3.5% 
of the patients with FD.
34 In a study from Hong Kong using the 
Rome I criteria, overlapping IBS was found to be 16.9% of the 
subjects with dyspepsia.
35 In a Japanese study using the Rome II 
criteria for the diagnosis of functional GI disorders, 181 medical 
students were recruited, and the overlap of IBS was found to be 
66.7% of UD subjects.
36 In a Korean study of 476 patients with 
functional GI disorders according to the Rome II criteria, the 
overlap of IBS was found in 20.8% of FD patients.
26 In these 
studies, overlap of FD and IBS showed wide variation that might 
be due to diagnostic criteria, study populations, sociocultural is-
sues, or symptom reporting by the patients.
Statement 10. Patients with functional dyspepsia may 
have overlap with gastroesophageal reflux disease.
Grade of evidence: moderate.
Level of agreement: a: 84.2%; b: 15.8%; c: 0%; d: 0%; e: 
0%; f: 0%.
Overlap of FD and gastroesophageal reflux disease (GERD) 
is common in different Asian populations.
23 A study from Turkey 
showed overlap of GERD to be 29.4% of subjects with symp-
toms of dyspepsia,
37 and a study from Korea showed such overlap 
to be 24.1% of FD subjects.
38 In both of those studies, GERD 
was diagnosed by questionnaire and not by 24-hour pH-im-
pedance monitoring, which is currently the gold standard for di-
agnosis of GERD. Heartburn, which is the major symptom of 
GERD, may be influenced by the type of reporting by the pa-
tients because of sociocultural issues and lack of appropriate ter-
minology in some Asian languages.
39 
Statement 11. Quality of life is impaired in patients with 
functional dyspepsia.
Grade of evidence: moderate.
Level of agreement: a: 84.2%; b: 15.8%; c: 0%; d: 0%; e: 
0%; f: 0%.
Quality of life (QOL) is not good in patients with FD al-
though it is not a fatal disease. The impairment of QOL in FD 
patients may be associated with significant burden on society due 
to work absenteeism, reduced productivity, and use of health care 
resources.
40,41 Data on QOL of patients with FD from Asia are 
scanty. However, in a Korean study of 1,417 subjects, the fre-
quency of dyspepsia was found to be 11.7% according to the 
Rome III criteria. The Korean version of SF-36 was used to eval-
uate health-related QOL, and in patients with dyspepsia, the 
scores were worse for all 8 domains.
42,43 Two studies from 
Malaysia by the same working team, one on a rural population 
and other on an urban population, showed using the EuroQOL 
(EQ-5D) instrument that subjects with dyspepsia (Rome II and 
III criteria) had lower health-related QOL.
44-46
Statement 12. Psychological co-morbidity and socio-
economic factors may determine consultation behavior 
among patients with functional dyspepsia.
Grade of evidence: moderate.
Level of agreement: a: 100.0%; b: 0%; c: 0%; d: 0%; e: 0%; 
f: 0%.
Psychological illness is often associated with FD. In a 
Chinese study, psychological co-morbidity was assessed by the 
Hamilton Rating Scale for Depression (HRSD) and the 
Hamilton Anxiety Scale (HAS) in patients with FD and in 
healthy subjects before and after treatment for this disease.
47 The 
data revealed a significant difference in HRSD and HAS scores 
between the FD patients and healthy subjects. Also, treatment 
with anti-depressant for 8 weeks resulted in improvement in 
scores. In a prospective, cross-sectional Malaysian study of 839 
patients with dyspepsia, there were 472 patients with FD and 367 
patients with organic causes.
48 This study showed that anxiety 
was associated with both groups and that health-related QOL 
was lower in the patients with FD than in the patients with organ-
ic dyspepsia. Psychological factors associated with FD may influ-
ence consultation behavior in patients with FD. A population- 
based study from Hong Kong revealed that anxiety was asso-
ciated with medical consultation and sick leave among patients 
with dyspepsia.
35 The study showed that the degree of anxiety 
was an independent factor associated with health care-seeking be-
havior in dyspeptic patients. However, bloating and incomplete Asian Consensus Report on Functional Dyspepsia
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evacuation were found to be more important determinants of con-
sultation behavior than psychological factors in a recent review of 
the epidemiology of IBS, which is another common functional 
bowel disease that may have overlapping dyspeptic symptoms.
49 
More studies on this issue are needed.
Pathophysiology
Statement 13. Pathogenesis of functional dyspepsia is 
multifactorial.
Grade of evidence: high.
Level of agreement: a: 100.0%; b: 0%; c: 0%; d: 0%; e: 0%; 
f: 0%.
Many pathogenic factors have been proposed for FD, in-
cluding motility abnormalities such as delayed gastric emptying, 
impaired gastric accommodation and hypersensitivity to gastric 
distension; psychological factors; excessive gastric acid secretion; 
H. pylori infection; genetic factors; environment in childhood 
and/or adolescence; diet; lifestyle; and prior GI infection.
50-52 
The major mechanism thought to induce FD symptoms includes 
impaired accommodation, delayed gastric emptying, and visceral 
hypersensitivity, as well as other complicating factors.
51,53 
Pharmacological correction of abnormal gastric motility and vis-
ceral hypersensitivity has been considered as a valid therapeutic 
approach in FD; however, changes in motor function and symp-
tomatic outcomes are poorly correlated.
54
Current evidence suggests that FD is a heterogeneous dis-
order in which different pathophysiological disturbances are as-
sociated with different symptom profiles. Progress in under-
standing the underlying pathogenetic mechanisms should lead to 
better targeting of treatment in FD patients.
50
Statement 14. Disturbed gastroduodenal motility is one 
of the pathophysiologic mechanisms in functional dys-
pepsia.
Grade of evidence: high.
Level of agreement: a: 100.0%; b: 0%; c: 0%; d: 0%; e: 0%; 
f: 0%.
Disturbed gastroduodenal motility is considered to be one of 
the major pathophysiologic mechanisms in FD.
4,51 Abnormal 
gastric motility has been analyzed from different aspects by vari-
ous measures, and differences in findings between health and dis-
eases have been characterized.
We intuitively recognize that delayed gastric emptying may 
be related to dyspeptic symptoms, especially feelings of retention 
of ingested food after meal, which can be abdominal distension, 
bloating or fullness. There are many reports demonstrating de-
layed gastric emptying in patients with FD from both Wes-
tern
55,56 and Asian
57-63 countries, and about 40% of FD patients 
are thought to show delayed gastric emptying after ingestion of 
solid food.
64 However, there are many studies that failed to show 
a direct connection between delayed gastric emptying and dys-
peptic symptoms,
65-67 suggesting that the relationship may not be 
entirely clear.
On the other hand, much attention has recently been paid to 
impaired gastric accommodation, which is also known as adaptive 
relaxation. The accommodation reflex is a volume response of the 
upper part of the stomach after a meal. After ingestion of food, 
the gastric fundus spontaneously dilates and begins to store food. 
Such impairment of gastric accommodation is known to correlate 
well with dyspeptic symptoms, especially early satiety.
68,69 How-
ever, this relationship has not been confirmed well in studies from 
some Asian countries.
70,71 
Statement 15. Visceral hypersensitivity is one of the 
pathophysiologic mechanisms in functional dyspepsia.
Grade of evidence: high.
Level of agreement: a: 100.0%; b: 0%; c: 0%; d: 0%; e: 0%; 
f: 0%.
Visceral hypersensitivity has been reported to play a key role 
in the pathophysiology of FD. Several studies have clearly dem-
onstrated that, as a group, patients with FD have enhanced sensi-
tivity to distension of the proximal stomach.
71-73 Abnormal central 
nervous system processing of visceral stimuli can be involved in 
hypersensitivity to proximal gastric distention. Patients with FD, 
who have hypersensitivity to gastric distension, more often report 
pain due to hyperalgesia.
74 Pain occurs in hypersensitive dyspep-
tic patients at distending pressures that induce non-painful 
sensations. In these patients, various luminal stimuli including 
chemical and mechanical stimuli can be perceived as unpleasant 
discomfort or pain. A study from the West reveals that hyper-
sensitivity to gastric distention is found in 34% of patients with 
FD.
73 A study from Korea showed that 37.5% of Korean patients 
with FD had hypersensitivity to gastric distension.
71 Although 
there is a report showing the association of this mechanism with 
symptoms of postprandial epigastric pain, belching and weight 
loss,
73 this association has not been clearly established yet, partic-
ularly in Asia.
71
Hypersensitivity to endogenous and exogenous chemicals, 
gastric acid or nutrients has been suggested to be associated with 
dyspeptic symptoms.
75-77 Since patients with visceral hyper-
sensitivity are considered to have enhanced sensory nerve activity, 
stimulation of luminal chemoreceptors in the upper GI mucosa Hiroto Miwa, et al
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may generate or aggravate dyspeptic symptoms. However, data 
on the prevalence and pathogenetic role of hypersensitivity to 
chemicals and nutrients in Asian patients with FD are lacking.
Statement 16. Psychosocial factors may play a role in 
functional dyspepsia.
Grade of evidence: moderate.
Level of agreement: a: 84.2%; b: 15.8%; c: 0%; d: 0%; e: 
0%; f: 0%.
Psychological disturbances have been proposed as one of the 
possible causes of FD.
48 Several population-based studies dem-
onstrated that patients with FD have higher prevalence of depres-
sion and anxiety compared to control population and even pa-
tients with organic dyspepsia.
48,78-80 It was shown that there is a 
gradual transition from mild to severe psychosocial morbidity 
parallel with dyspepsia symptom severity,
78,81 and Hsu et al
82 
found that patients fulfilling the criteria for either postprandial 
distress syndrome or epigastric pain syndrome had psychologi-
cally more severe symptoms. In clinical practice, anti-anxiety or 
anti-depressive agents are sometimes prescribed for symptoms of 
FD. On the basis of a systematic review of the literature, Hojo et 
al
83 concluded that anti-anxiety and anti-depressive agents may 
be effective treatments for FD.
Stressful life events in the patient’s social environment are al-
so thought to be associated with the onset or exacerbation of dys-
peptic symptoms, although the relationship is still not clear. Some 
studies have shown that the number of stressful life events experi-
enced by FD patients was more than that experienced by healthy 
controls,
79,84,85 whereas others have found no significant differ-
ence in the number of such events.
84,86 Hui et al
86 indicated that 
differences in FD symptoms correlated with psychological fac-
tors such as negative perception of major life events rather than 
with the number of stressful life events experienced. Chen et al
87 
demonstrated that severity of stressful life events was positively 
correlated with disturbance of gastric myoelectric activity in FD 
patients. Coping pattern is a psychological factor associated with 
FD symptoms.
84,86,88 Several psychological studies have found 
that effective coping strategies play a role in mitigating anxiety, 
depression and somatic problems.
88,89 Cheng et al
89 designed 
flexible coping psychotherapy for enhancing coping flexibility of 
FD patients and demonstrated that the psychotherapy sig-
nificantly changed FD symptom severity. Lastly, familial factors 
may include psychological, environmental or genetic factors, 
which may contribute to abdominal symptoms of FD patients. 
Ahn et al
90 found that family function score was lower in an FD 
group than in a normal control group, and Ochi et al
91 suggested 
that parental criticism experienced in early life may underlie the 
psychological background of FD patients and correlated with 
their abdominal symptoms. All these results add support to the 
theory of psychosocial disturbances in the pathogenesis of FD.
Statement 17. Gastric acid may be responsible for the 
symptoms in a subset of patients with functional dyspep-
sia.
Grade of evidence: moderate.
Level of agreement: a: 89.5%; b: 10.5%; c: 0%; d: 0%; e: 
0%; f: 0%.
Because anti-secretory therapy is effective in some patients 
with FD,
92,93 it is thought that gastric acid may play a role in the 
pathogenesis of FD. However, it has not been clearly demon-
strated that excessive gastric acid is a pathogenetic factor in FD, 
and data on the amount of gastric acid secretion in patients with 
FD are lacking. Results of studies from Asian countries are 
controversial.
94-96
Proton pump inhibitors (PPIs) are believed to be beneficial 
in a subset of patients with FD. This positive response is mainly 
confined to patients with ulcer-like and reflux-like dyspepsia.
92 
Patients with postprandial pain are reported to have a high preva-
lence of pathological acid exposure, which suggests that patients 
who respond to acid-suppressive therapy might have non-erosive 
reflux disease.
97 Several studies have suggested a role for in-
creased duodenal acid exposure or duodenal or gastric hyper-
sensitivity to acid in the pathogenesis of symptoms in some pa-
tients with FD.
76,98-100 These factors might explain the beneficial 
effects of acid-suppressive treatment for FD. However, the prev-
alence and pathogenetic role of these abnormalities in Asian pa-
tients with FD remains to be further explored.
Statement 18. Helicobacter pylori may play a role in 
pathogenesis of functional dyspepsia.
Grade of evidence: moderate.
Level of agreement: a: 52.6%; b: 31.6%; c: 5.3%; d: 10.5%; 
e: 0%; f: 0%.
The reported prevalence of H. pylori infection in patients with 
FD varies from 39% to 87%.
101 Several epidemiological studies 
have shown that H. pylori infection occurs more frequently in FD 
than in matched control populations. A meta-analysis published 
in 1999 reported a summary odds ratio for H. pylori infection in 
FD of 1.6 (95% CI, 1.4-1.8).
102 Mechanistic studies found that 
H. pylori-infected FD patients had higher stimulated gastric acid 
output than H. pylori-negative healthy volunteers.
103 However, 
no associations between H. pylori positivity and symptom pattern, 
gastric emptying rate, gastric accommodation or sensitivity to dis-Asian Consensus Report on Functional Dyspepsia
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tension in FD patients have been found.
104
The effect of H. pylori eradication on dyspeptic symptoms in 
FD patients has been evaluated in several large, well-designed, 
randomized controlled trials, but the results were conflic-
ting.
105,106 Conflicting data have also been reported from 
Asia.
29,107 Wong et al
108 found that the standard treatment for H. 
pylori infection is suboptimal in FD compared with duodenal 
ulcer. A Cochrane systematic review showed that there was a 10% 
relative risk reduction in the H. pylori eradication group com-
pared to placebo, and that the number needed to treat to cure one 
case of dyspepsia was 14.
109 However, a recently published sys-
tematic review and meta-analysis from the Chinese literature 
found that the summary odds ratio for improvement in dyspeptic 
symptoms in patients with FD after H. pylori eradication was 
3.61, suggesting that the role of this infection is much larger in 
the Chinese population than in Western populations.
110
Some of the consensus members proposed that dyspepsia ac-
companied by H. pylori infection should be regarded as a differ-
ent disease entity from FD. In other words, FD patients should 
be H. pylori-negative and H. pylori infection should be eradicated 
before making a diagnosis of FD. The logic behind this opinion 
was (1) histological gastritis is no longer a non-organic disease as 
it can be visually recognized by advanced endoscopic tech-
nologies, such as magnifying or narrow band imaging endoscopy; 
(2) H. pylori eradication is strongly recommended regardless of 
the presence of dyspeptic symptoms, especially in some Asian 
countries where gastric cancer is highly prevalent; and (3) the 
concept of post-infectious FD has already been recognized and 
H. pylori infection is apparently an infection that causes mucosal 
inflammation.
Statement 19. Post-infectious functional dyspepsia occurs 
in a subset of patients.
Grade of evidence: moderate.
Level of agreement: a: 73.7%; b: 26.3%; c: 0%; d: 0%; e: 
0%; f: 0%.
FD has been reported to occur in patients following GI 
infection. In a prospective study from Spain, 14% of persons who 
were infected by shigella developed post-infectious dyspepsia, re-
sulting in a relative risk of 5.2 compared to controls.
111 Further-
more, a number of reports from Europe and Asia have shown 
that low-grade inflammation is found in the duodenum of pa-
tients with post-infectious FD.
112,113 In a large retrospective ter-
tiary center study, Tack et al
114 showed that a subset of presumed 
post-infectious dyspepsia patients had higher prevalence of im-
paired accommodation of the proximal stomach. There is evi-
dence that post-infectious FD can occur in a subset of patients, 
and functional abnormalities and persistent inflammation of the 
gut are found.
Statement 20. Genetic factors may be involved in 
pathogenesis in a subset of patients with functional 
dyspepsia.
Grade of evidence: low.
Level of agreement: a: 78.9%; b: 15.8%; c: 5.3%; d: 0%; e: 
0%; f: 0%.
The G-protein β3 subunit C825T polymorphism was re-
ported to be associated with dyspepsia in studies from the United 
States (both CC and TT genotypes with meal-unrelated dyspep-
sia)
115 and Germany (CC genotype).
116　In contrast, the 825-T al-
lele was suggested to be related to dyspepsia in reports from 
Japan and the Netherlands.
117-119 In Japanese groups, the follow-
ing polymorphisms have been reported to be associated with the 
development of FD or dyspeptic symptoms: IL-17F 7488T, 
macrophage migration inhibitory factor G-173C,
120 catechol-o- 
methyltransferase gene val158met,
121 T779C of cholecystokinin-1 
intron 1,
122 cyclooxygenase-1 T-1676C,
123 p22 phagocyte oxidase 
component of nicotinamide adenine dinucleotide phosphate oxi-
dase C242T
124 and transient receptor potential vanilloid 1 
G315C.
125 These data indicate that genetic factors are associated 
with the development of FD. However, the studies from Asia are 
limited and are only from Japan. Validation in other countries and 
in a large-scale study is warranted.
Statement 21. Dietary factors and lifestyle may be 
involved in the pathogenesis of functional dyspepsia.
Grade of evidence: low.
Level of agreement: a: 94.7%; b: 5.3%; c: 0%; d: 0%; e: 0%; 
f: 0%.
The investigation of lifestyle factors in FD has been limited 
to a few studies. From Asia, Chen et al
79 and Mahadeva et al
44 re-
ported that tea drinking was negatively associated with FD. 
Theophylline in tea acts as a competitive antagonist to adenosine 
receptors, which induce epigastric pain and chest pain.
126,127 
However, there is little Asian literature on the types and amounts 
of tea drunk by dyspeptic patients.
More recently, the concept of visceral hypersensitivity to nu-
trient stimuli, especially hypersensitivity to fat,
128,129 has been 
highlighted as an etiology of FD.
130,131 Food ingestion is asso-
ciated with stimulation of secretion of a range of GI hormones, 
including cholecystokinin and peptide YY, and suppression of 
ghrelin.
132 It is conceivable that gut peptides play a role in the in-
duction of dyspeptic symptoms in FD patients with nutrient Hiroto Miwa, et al
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hypersensitivity. In patients with FD, intolerance to specific 
foods is common and many foods are reported to induce 
symptoms.
133 On the contrary, chili and rice
134 and ginger
135 are 
reported to be good for dyspepsia. Feinle-Bisset et al
136 reported 
that postprandial fullness is the most severe symptom in patients 
reporting aggravation by meal.
Most studies concerning the relationships between lifestyle 
or dietary factors and FD are based on symptom intensities eval-
uated by questionnaire or on physiological studies involving par-
ticular foods or components. Further prospective studies are nec-
essary to clarify the details of these pathogenetic factors and the 
role of dietary therapy in the management of FD.
Management
Statement 22. An integrated approach addressing 
physiological, biological, psychological and social factors 
is recommended for all patients with functional dyspep-
sia (see Fig. 2).
Grade of evidence: low.
Strength of recommendation: probably do it.
Level of agreement: a: 84.2%; b: 10.5%; c: 5.3%; d: 0%; e: 
0%; f: 0%.
As the pathogenesis of FD is multi-factorial, treatment 
should be individualized, with an effort to identify as many possi-
ble putative factors as possible. There have been no direct data to 
support this approach to managing FD in general. On the other 
hand, there have been studies on IBS that demonstrate a favor-
able response to treatment when physicians make an effort to ad-
dress possible contributing factors such as past GI infection 
(biological), psychosocial stressors (psychological) and dietary 
changes (social), to reassure the patient by providing reasonable 
evidence that he or she does not have a life-threatening condition, 
and to explain the diagnosis with appropriate pathophysiological 
(physiological) models. In view of the overlap in symptoms, pa-
tient demographics and putative pathophysiology, it is reasonable 
to recommend a similar approach to FD, as was recommended in 
the recent Asian IBS Consensus.
137-139
There is a study to support adopting a combination of in-
tensive medical therapy with psychological intervention in pa-
tients with refractory FD. Haag et al,
140 in a prospective random-
ized, controlled trial, compared the long-term outcome of in-
tensive medical therapy (with or without cognitive-behavioral or 
muscle relaxation therapy) versus standard medical therapy in pa-
tients with refractory FD and found that in FD patients with re-
fractory symptoms, intensified medical management involving 
function testing and psychological intervention yielded superior 
long-term outcomes. There is also a study from China that 
showed psychological intervention to be superior to prokinetic 
therapy.
141
Statement 23. Where socio-economic conditions allow, 
Helicobacter pylori testing and eradication should be 
part of the management strategy for all patients in Asia 
who present with dyspepsia (see Fig. 2).
Grade of evidence: high.
Strength of recommendation: do it.
Level of agreement: a: 58.0%; b: 42.0%; c: 0%; d: 0%; e: 
0%; f: 0%.
H. pylori eradication has a statistically significant effect on 
symptom relief in patients with FD. Cochrane meta-analysis on 
17 randomized controlled trials (n = 3,566) found a small but 
statistically significant benefit of H. pylori eradication therapy at 
12 months, with relative risk reduction of 10% (95% CI, 
6%-14%) and number needed to treat of 14 (95% CI, 10-25).
109 
Studies from Asia included in this meta-analysis showed both 
positive
142,143 and negative
107,144 results. However, in a recent 
meta-analysis of 7 Chinese studies,
110 the summary odds ratio for 
symptom improvement by H. pylori eradication was 3.61 (95% 
CI, 2.62-4.98; P < 0.0001), which was far higher than those of 
previously published meta-analyses. Recent studies from Singa-
pore also support the role of H. pylori eradication in FD,
145,146 
suggesting that the benefit of H. pylori eradication therapy is pos-
sibly more significant in the Asian region. However, benefits of 
this strategy should be weighed against its costs including possi-
ble induction of high rate of antibiotic resistance in addition to the 
high financial burden in areas with high prevalence of H. pylori 
infection.
The recently published Asia Pacific consensus guidelines on 
H. pylori infection stated, “H. pylori eradication is indicated for 
H. pylori-positive patients with investigated dyspepsia (non-ulcer 
dyspepsia).”
147 The basis for the recommendation, which was 
itemized by the guidelines, included the benefit of H. pylori erad-
ication from the social aspect. In other words, eradication of H. 
pylori in patients with FD has the additional benefit of reducing 
the risks for peptic ulcer disease and gastric cancer.
In studies from South America and China, regions with high 
prevalence rates of H. pylori infection and high incidence rates of 
gastric cancer, H. pylori eradication produced significant in-
creases in the rates of regression of intestinal metaplasia and gas-
tric atrophy and lowered the risk of progression to intestinal met-
aplasia,
148-153 providing evidence that H. pylori eradication has a Asian Consensus Report on Functional Dyspepsia
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direct impact on gastric cancer occurrence and reduces the risk of 
metachronous gastric cancer after endoscopic resection. A 
meta-analysis
154 of 6 randomized placebo-controlled H. pylori 
eradication trials
148,151,152,155-157 showed that with H. pylori erad-
ication, the pooled relative risk of developing gastric cancer was 
0.65 (95% CI, 0.43-0.98).
Considering all these data, the management algorithm rec-
ommended to eradicate H. pylori if socioeconomic conditions al-
low (Fig. 2).
Statement 24. Proton pump inhibitors are effective for 
controlling symptoms in patients with functional dyspep-
sia, although supportive data from Asia are lacking (see 
Fig. 2).
Grade of evidence: moderate.
Strength of recommendation: do it.
Level of agreement: a: 75.0%; b: 25.0%; c: 0%; d: 0%; e: 
0%; f: 0%.
The rationale for using PPIs in FD stems from both clinical 
as well as physiological perspectives. Studies showing overlap be-
tween non-erosive reflux disease (NERD) and FD also support 
use of PPI in patients with FD.
158-161 Besides this, pathological 
esophageal acid exposure has been reported in Western FD pa-
tients without symptoms of heartburn.
97,162 
To date, 7 randomized controlled trials of PPI versus place-
bo have been reported.
92,95,163-167 Six of the 7 studies were con-
ducted in Western population and they demonstrated a benefit 
over placebo for symptom improvement in FD patients,
92,163-167 
though PPIs may not be effective in dysmotility-like dyspep-
sia.
168 In fact, the combined effect of all 7 trials (2,387 PPI pa-
tients, 1,338 placebo patients) was expressed in a recent 
meta-analysis,
169 which reported that there was a modest but stat-
istically significant difference in symptom relief in patients receiv-
ing PPIs (40.3%) compared with those given placebo (32.7%), 
and the estimated number needed to treat was 14.6 patients (95% 
CI, 8.7-57.1).
It must be noted that the only trial that showed negative re-
sults among the 7 trials in the above-mentioned meta-analysis was 
from Hong Kong. In addition, a recent randomized trial from 
Hong Kong that investigated the efficacy of a PPI on H. pylo-
ri-negative uninvestigated dyspeptic patients (epigastric pain and 
discomfort) also failed to show an efficacy of PPI over placebo.
96 
An open-labelled study from Singapore, also reported only a 
modest response to PPI.
170 Characteristic differences between 
Asian and Western patients with FD may explain the lower bene-
fit of PPIs in Asian patients. These data suggest that the efficacy 
of PPIs in patients with FD needs to be reevaluated in the Asian 
population.
Statement 25. High-dose proton pump inhibitor therapy 
is not superior to standard doses for symptom control in 
functional dyspepsia.
Grade of evidence: moderate.
Strength of recommendation: probably not do it.
Level of agreement: a: 65.0%; b: 25.0%; c: 10.0%; d: 0%; e: 
0%; f: 0%.
Several studies have examined the role of standard and high-
er doses of PPI in the treatment of FD.
95,164-166,168 Whether the 
patients responded to PPIs or not, these studies, which involved a 
large number of patients, consistently found no difference in 
symptom response between standard and higher PPI doses. A re-
cent meta-analysis also concluded that the dose of PPI did not in-
fluence the response of FD symptoms to treatment.
169 It is there-
fore proposed that a standard dose of PPI is sufficient in the 
management of FD, and that dose escalation is unlikely to further 
reduce symptoms.
Another concern regarding the use of higher doses of PPI in 
patients with FD relates to incurring unwanted problems caused 
by acid inhibition. Recent studies of healthy, asymptomatic vol-
unteers who received PPI treatment for either 4 or 8 weeks dem-
onstrated rebound acid hypersecretion following withdrawal of 
the PPI, resulting in the development of dyspeptic symptoms af-
ter PPI treatment.
171,172 Yet another concern regarding PPI ad-
ministration relates to the development of small intestinal bacte-
rial overgrowth (SIBO) in patients receiving long-term the-
rapy.
173 Although long-term PPI therapy has not been advocated 
in FD, the risk of SIBO may be greater in patients on higher PPI 
doses than in patients on standard PPI doses.
173
Statement 26. Prokinetics may provide symptom relief in 
some functional dyspepsia patients (see Fig. 2).
Grade of evidence: moderate.
Strength of recommendation: do it.
Level of agreement: a: 90.0%; b: 10.0%; c: 0%; d: 0%; e: 
0%; f: 0%.
Prokinetic agents, such as metoclopramide, domperidone, 
trimebutine, cisapride, itopride, mosapride, levosulpiride and ci-
nitapride, can stimulate digestive tract motility via different 
mechanisms. Use of cisapride is currently restricted in most 
Asian countries because of its cardiovascular complications. 
Because delayed gastric emptying is considered a potential con-
tributing factor to FD symptoms, prokinetic agents are often 
used in FD. In a meta-analysis from the Cochrane library that in-Hiroto Miwa, et al
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cluded 24 randomized controlled trials with 3,178 patients, the 
efficacy of prokinetics was superior to placebo (57% vs 47%).
93 
However, studies on prokinetics in FD had limitations due to the 
high degree of heterogenicity and small sample size.
93,174
The clinical trial data for the new drug acotiamide showed a 
clear margin of symptom improvement compared with placebo, 
and may be approved for FD of the postprandial distress syn-
drome subtype.
175,176
Statement 27. Some studies from Asia reported that 
herbal medications provide symptom relief in functional 
dyspepsia (see Fig. 2).
Grade of evidence: moderate.
Strength of recommendation: probably do it.
Level of agreement: a: 60.0%; b: 40.0%; c: 0%; d: 0%; e: 
0%; f: 0%.
Limited studies have shown potential benefit of herbal medi-
cines for symptom relief in FD patients. In a meta-analysis that 
included 33 studies on the efficacy of xiaoyao san (XS),
177 a 
well-known traditional Chinese herbal formula for FD treatment, 
modified XS without (OR, 3.26; 95% CI, 2.24-4.47) or with 
(OR, 4.32; 95% CI, 2.64-7.08) prokinetics significantly reduced 
symptoms compared with prokinetics alone. However, the re-
porting of quality issues in these studies was generally poor. 
These studies are usually non-randomized, non-blinded and 
without placebo control. Therefore, high-quality controlled trials 
are required to assess the effects of XS in comparison to placebo. 
Another relatively small-scaled but placebo-controlled study 
from Japan demonstrated the efficacy of the Japanese herbal 
medicine rikkunshito (TJ-43) in reducing GI symptoms in FD 
patients and accelerating gastric emptying.
178 This medicine was 
found to improve gastric accommodation in a study using ex-
tracorporeal ultrasonography.
179
Statement 28. Anti-depressant and anxiolytic agents have 
a role in the management of functional dyspepsia, despite 
the limited evidence (see Fig. 2).
Grade of evidence: low.
Strength of recommendation: probably do it.
Level of agreement: a: 80.0%; b: 20.0%; c: 0%; d: 0%; e: 
0%; f: 0%.
Evidence supporting the use of psychotherapy in treatment 
of FD is inconsistent and weak.
180 As for pharmacological thera-
pies, only limited studies of anti-depressants or anxiolytic drugs 
are available. In a small study involving only 7 FD patients with 
sleep disturbance, low-dose amitriptyline improved dyspeptic 
symptoms more than placebo did.
181 In a series of studies from 
Dublin, buspirone, a partial 5-hydroxytryptamine 1A (5-HT1A) 
agonist with anti-depressant and anxiolytic effects, was shown to 
improve dyspeptic symptoms in FD, with associated enhanced 
prolactin release in FD patients compared with controls, suggest-
ing that central HT1A receptors may be supersensitive in FD 
patients.
182-184 A recent study from Japan showed that symptom 
resolution was significantly greater in FD patients treated with 
tandospirone, a 5-HT1A agonist with anxiolytic activity, than in 
patients given a placebo.
185 On the contrary, venlafaxine, a sero-
tonin and norepinephrine reuptake inhibitor, failed to show pos-
itive results and a greater number of patients on venlafaxine than 
on placebo dropped out of the study because of side effects.
186 
Central factors, such as psychological disturbance, sleep dis-
turbance and central serotonin receptor sensitivity, may be im-
portant determinants of response to anti-depressant treatment in 
FD patients. In an open-label study from Taiwan, fluoxetine im-
proved GI symptoms in depressed but not in non-depressed FD 
patients,
187 and in a study from Norway, high levels of neuroti-
cism and concealed aggressiveness predicted poor response to 
mianserin, a tetracyclic anti-depressant.
188
Statement 29. Specific food ingredients such as chili, 
spice and fats may provoke dyspeptic symptoms. Dietary 
modification can be considered in functional dyspepsia 
but data are lacking (see Fig. 2).
Grade of evidence: low.
Strength of recommendation: probably do it.
Level of agreement: a: 80.0%; b: 20.0%; c: 0%; d: 0%; e: 
0%; f: 0%.
Although patients frequently believe that certain foods are 
the cause of their symptoms, there are few good studies to exclude 
the effect of psychological bias in the patient’s perception. 
However, experimental studies suggest that certain food in-
gredients such as chili, spice and fats may provoke dyspeptic 
symptoms. Most importantly, there is no well-controlled study to 
demonstrate that dietary exclusion of specific food ingredients is 
effective for symptom control in FD. 
45,128,129,133,134,136,189-196
Conclusion
This consensus was developed to attract attention to the data 
from Asian countries, to articulate the experience and views of 
Asian experts, and to provide a relevant guide on management of 
FD for primary care physicians working in Asia. This consensus 
shows distinctive features of FD in Asia and will provide a guide 
to the diagnosis and management of FD for Asian primary care Asian Consensus Report on Functional Dyspepsia
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physicians. The understanding of FD is still incomplete and is 
evolving over time and this consensus report will be revised as our 
understanding of FD grows.
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